Company: SNPS
Filing Date: 2025-06-30
Form Type: 425
Source: 0001140361-25-024106
Chunk: 1

Company: SYNOPSYS INC
Filing Date: 2025-06-30
Form: 425
Chunk 1
---
 names may be trademarks of their respective owners.

INVESTOR CONTACT:

Trey Campbell

Synopsys, Inc.

650-584-4289

Synopsys-ir@synopsys.com

Kelsey DeBriyn

ANSYS, Inc.

724-820-3927

kelsey.debriyn@ansys.com**

<div align='center'>1</div>

**EDITORIAL CONTACTS:

Cara Walker

Synopsys, Inc.

650-584-5000

corp-pr@synopsys.com

Mary Kate Joyce

ANSYS, Inc.

724-820-4368

MaryKate.Joyce@ansys.com

Cautionary Statement Regarding Forward-Looking Statements

This communication may contain certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Synopsys and Ansys, including, but not limited to, statements regarding the
          anticipated timing of the closing thereof and the regulatory approvals required for completion of the proposed transaction. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,”
          “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negatives of these words or other comparable terminology to
          convey uncertainty of future events or outcomes.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks, uncertainties and other factors that could cause
          actual future events to differ materially from the forward-looking statements in this communication, including, but not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, (ii) the failure to satisfy the
          conditions to the consummation of the proposed transaction, including the receipt of certain governmental and regulatory approvals on the terms expected, in a timely manner, or at all, (iii) the risk that such regulatory approvals may result in
          the imposition of conditions that could adversely affect, following completion of the proposed transaction (if completed), the combined company or the expected benefits of the proposed transaction, (iv) the occurrence of any event, change or
          other circumstance that could give rise to the termination of the merger agreement, (v) the effect of the pendency of the proposed transaction on